SCHEMBL1015522

SCHEMBL1015522

O=C(COCC(=O)NC1CCCCCCCCCCC1)Nc1ccc(Cl)cc1C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.55
NPC1 O15118 3/20 0.55
KDM4E B2RXH2 3/20 0.54
LMNA P02545 2/20 0.54
ALDH1A1 P00352 2/20 0.54
RXFP1 Q9HBX9 1/20 0.54
SERPINE1 P05121 4/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
HSD17B10 Q99714 2/20 0.51
HPGD P15428 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.50
POLB P06746 2/20 0.49
KMT2A Q03164 1/20 0.49
G6PD P11413 1/20 0.49
EPHX2 P34913 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1015912 0.89 RAB9A (0.55) RAB9ANPC1KDM4ELMNAALDH1A1
SCHEMBL1015064 0.84 HPGD (0.56) RAB9ANPC1KDM4ELMNAALDH1A1
SCHEMBL1015397 0.84 SERPINE1 (0.50) KDM4EALDH1A1SERPINE1HSD17B10L3MBTL1
SCHEMBL1013771 0.83 SERPINE1 (0.49) KDM4EALDH1A1SERPINE1HSD17B10L3MBTL1
SCHEMBL1015276 0.83 SERPINE1 (0.65) NPC1KDM4EALDH1A1SERPINE1HSD17B10
SCHEMBL1012592 0.82 SERPINE1 (0.64) NPC1KDM4EALDH1A1SERPINE1HSD17B10
SCHEMBL1015307 0.80 SERPINE1 (0.64) KDM4EALDH1A1SERPINE1HSD17B10L3MBTL1
SCHEMBL1796545 0.80 SERPINE1 (0.51) RAB9ANPC1KDM4EALDH1A1SERPINE1
SCHEMBL1014856 0.79 SERPINE1 (0.51) RAB9ANPC1KDM4ELMNAALDH1A1
SCHEMBL1797569 0.79 SERPINE1 (0.56) KDM4EALDH1A1SERPINE1SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US claimed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US claimed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP claimed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 RAB9A 2950/4885NPC1 1613/4885KDM4E 4108/4885
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 RAB9A 2760/4885NPC1 2092/4885KDM4E 4253/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 RAB9A 2814/4885NPC1 1925/4885KDM4E 4348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.